Abstract
Background: Diagnostic coronary angiography is oftenfol‐lowed by coronary stenting. Therapy with aspirin and clopidogrel is currently the standard treatment for patients undergoing coronary stenting. Clopidogrel loading is usually given prior to the procedure. Some pretreated patients, however, are found to have triple‐vessel disease (3 VD) or left main disease (LMD) that requires referral for coronary artery bypass graft (CABG) surgery. Surgery in patients pretreated with clopidogrel may be complicated by excessive bleeding or delayed to avoid that risk.
Hypothesis: A risk factor‐based formula may predict the likelihood that patients referred for coronary angiography will have 3VD or LMD.
Methods: Consecutive patients (n= 2,180) referred for coronary angiography constitute the training subset (n = 1,296) used to build the model, and the validation subset (n = 884) used to test the model. Logistic regression models selected five variables showing strong associations with the presence of 3VD or LMD: age, gender, diabetes, hypercholesterolemia, and prior myocardial infarction (MI). A formula based on these variables and on the training subset was constructed to calculate the probability of 3 VD or LMD.
Results: Applying this model to the validation subset predicted 3 VD or LMD with 79% sensitivity, 53% specificity, 45% positive predictive value, and 83% negative predictive value.
Conclusions: This simple formula based on five clinical variables is helpful in predicting the likelihood that patients, referred for coronary angiography, will have 3 VD or LMD. Use of this formula can help decide in which patients clopidogrel loading prior to angiography should be avoided.
Keywords: clopidogrel, coronary stenting, coronary artery bypass graft
Full Text
The Full Text of this article is available as a PDF (39.0 KB).
References
- 1. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreatment with clopidogrel and aspirin followed by long‐term therapy in patients undergoing percutaneous coronary intervention: The PCI‐CURE study. Lancet 2001; 358: 527–533 [DOI] [PubMed] [Google Scholar]
- 2. Atmaca Y, Dandachi R, Gulec S, Dincer I, Oral D: Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting. Int J Cardiol 2003; 87: 143–149 [DOI] [PubMed] [Google Scholar]
- 3. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL: Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003; 145: 239–247 [DOI] [PubMed] [Google Scholar]
- 4. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002; 288: 2411–2420 [DOI] [PubMed] [Google Scholar]
- 5. Hongo RH, Ley J, Dick SE, Yee RR: The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231–237 [DOI] [PubMed] [Google Scholar]
- 6. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502 [DOI] [PubMed] [Google Scholar]
- 7. Berger PB, Steinhubl S: Clinical implications of percutaneous coronary intervention‐clopidogrel in unstable angina to prevent recurrent events (PCI‐CURE) study: AUS perspective. Circulation 2002; 106: 2284–2287 [DOI] [PubMed] [Google Scholar]
- 8. Levine GN, Kern MJ, Berger PB, Brown DL, Klein LW, Kereiakes DJ, Sanborn TA, Jacobs AK: Management of patients undergoing percutaneous coronary revascularization. Ann Intern Med 2003; 139: 123–136 [DOI] [PubMed] [Google Scholar]
- 9. Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ: Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one year survival: Results from the Do tirofiban and ReoPro give similar efficacy outcome trial (TARGET). J Am Coll Cardiol 2003; 1188–1195 [DOI] [PubMed] [Google Scholar]
- 10. Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirschinger J, Schomig A: Clopidogrel therapy in patients undergoing coronary stenting: Value of a high‐loading‐dose regimen. Cathet Cardiovasc Interv 2002; 55: 436–441 [DOI] [PubMed] [Google Scholar]
- 11. Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa‐Murray G, Schomig A, Gawaz M: Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92–93 [DOI] [PMC free article] [PubMed] [Google Scholar]